EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies

Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Fortunato Morabito, Massimo Gentile iD

European Journal of Haematology · 2026-03 · 116 (3) · 204-214

DOI: 10.1111/ejh.70065 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Haematology, online erschienen am 25.11.2025. Verfasst von Enrica Antonia Martino und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit, Department of Onco-Hematology, AO of Cosenza, Cosenza, Italy. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Infections. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Infections remain a leading cause of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL), reflecting both intrinsic immune dysfunction and therapy‐related immunosuppression. The pathogenesis of immunodeficiency in CLL is multifactorial: neoplastic B cells impair humoral immunity, T cells are functionally exhausted, and innate immune cells, particularly neutrophils and NK cells, display profound defects. Beyond impaired pathogen defense, these immune alterations actively support leukemic cell survival and promote a tolerogenic microenvironment. The advent of targeted therapies has reshaped the infectious risk profile. Bruton's tyrosine kinase inhibitors (BTKis) and venetoclax have largely replaced chemotherapy, reducing classic opportunistic infections but introducing new challenges. BTKis are associated with invasive fungal infections and increased pneumonia risk in combination regimens, while venetoclax frequently induces profound neutropenia. Anti‐CD20 monoclonal antibodies cause long‐lasting B‐cell depletion and viral reactivation. These evolving risks demand nuanced approaches to prevention. Prophylactic strategies must be individualized. Antiviral prophylaxis is warranted with anti‐CD20 antibodies and BTKis, and Pneumocystis jirovecii pneumonia (PJP) prophylaxis remains essential with fludarabine, cyclophosphamide, and rituximab (FCR) or prolonged corticosteroid therapy. Antifungal prophylaxis is not routinely indicated in CLL but may be considered in high‐risk patients on BTKis or with refractory disease. Immunoglobulin replacement therapy (IgRT) reduces recurrent bacterial infections in patients with hypogammaglobulinemia, while vaccination—though often limited by suboptimal responses—remains the cornerstone of prevention. Timing before therapy or during treatment‐free intervals is critical, and newer formulations, such as conjugate pneumococcal and recombinant zoster vaccines, are preferred. Future directions include developing predictive biomarkers of infection risk and vaccine responsiveness, integrating immune monitoring into clinical trials, and exploring strategies to modulate neutrophil plasticity and restore T‐cell function. Until then, a pragmatic, risk‐adapted approach combining vigilance, prophylaxis, immunoglobulin replacement, and optimized vaccination offers the best safeguard for patients with CLL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellInfectionsHumansRisk FactorsAntineoplastic Combined Chemotherapy ProtocolsDisease Management

Stichwörter der Autor:innen

Bruton's tyrosine kinase inhibitorschronic lymphocytic leukemiaimmunodeficiencyinfection prophylaxisvaccination

Autor:innen und Institutionen

  • Hematology Unit, Department of Onco-Hematology, AO of Cosenza, Cosenza, Italy.
  • Department of Experimental and Clinical Medicine, University of Catanzaro, Catanzaro, Italy.
  • AIL Sezione di Cosenza, Cosenza, Italy.
  • Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy.

ORCID-Profile: Massimo Gentile

Zitieren

APA

Martino, E. A., Caserta, S., Vigna, E., Bruzzese, A., Amodio, N., Lucia, E., Olivito, V., Labanca, C., Mendicino, F., Morabito, F., & Gentile, M. (2026). Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies. European Journal of Haematology, 116(3), 204-214. https://doi.org/10.1111/ejh.70065

Vancouver

Martino EA, Caserta S, Vigna E, Bruzzese A, Amodio N, Lucia E, et al. Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies. European Journal of Haematology. 2026;116(3):204-214. doi:10.1111/ejh.70065

BibTeX
@article{Martino2026,
  author = {Martino, Enrica Antonia and Caserta, Santino and Vigna, Ernesto and Bruzzese, Antonella and Amodio, Nicola and Lucia, Eugenio and Olivito, Virginia and Labanca, Caterina and Mendicino, Francesco and Morabito, Fortunato and Gentile, Massimo},
  title = {Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies},
  journal = {European Journal of Haematology},
  year = {2026},
  volume = {116},
  number = {3},
  pages = {204--214},
  doi = {10.1111/ejh.70065}
}
Kostenlos starten →